Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to transform cardiovascular disease prevention and early detection through precision medicine, as highlighted by CEO and Co-Founder Dr. Meesha Dogan in a recent interview on The BioMedWire Podcast. Dogan detailed the company's use of epigenetics, genetics, and artificial intelligence to develop personalized diagnostic tools, and emphasized the strategic importance of the company's expansion into India.
During the podcast, Dogan discussed Cardio Diagnostics' partnerships with Aimil Ltd. and Dr. Lal PathLabs, which aim to bring the company's innovative tests to the Indian market. This expansion is significant given India's high burden of cardiovascular disease and the potential for precision medicine to improve outcomes. The partnerships leverage the local expertise and distribution networks of these established diagnostic firms, positioning Cardio Diagnostics to reach a broad patient population.
Dogan also provided an update on the company's progress with Medicare reimbursement. She noted that the CPT coding and payment steps have been completed, which are critical for establishing a pathway to coverage. However, the coverage determination is still underway. Achieving Medicare coverage is crucial for widespread adoption of Cardio Diagnostics' tests, as it would enable broader access for elderly patients and signal validation from a major payer.
The company's technology is built on a proprietary AI-driven Integrated Genetic-Epigenetic Engine, which analyzes genetic and epigenetic markers to assess cardiovascular risk. This approach aims to move beyond traditional risk factors and provide more precise, personalized assessments. According to the company, this could lead to earlier interventions and better management of cardiovascular disease, which remains a leading cause of death globally.
Cardio Diagnostics' focus on precision medicine aligns with broader trends in healthcare toward personalized treatment. By integrating AI and epigenetics, the company seeks to address limitations of current screening methods, such as the reliance on cholesterol levels and blood pressure, which may miss individuals at risk. The India expansion and Medicare progress are key milestones that could accelerate adoption and revenue growth.
For more information, visit the company's newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/0VjIz.
